Travere therapeutics to present abstracts on filspari® (sparsentan) in iga nephropathy at world congress of nephrology and the american nephrology nurses association

San diego, april 03, 2024 (globe newswire) -- travere therapeutics, inc., (nasdaq: tvtx) today announced that the company will present nine abstracts in rare kidney disease at the world congress of nephrology (wcn) in buenos aires, argentina, on april 13-16, 2024, and the american nephrology nurses association (anna) national symposium in orlando, florida, on april 14-17, 2024. at wcn, the company will present subgroup analyses of the phase 3 protect study of filspari® (sparsentan) in iga nephropathy (igan) showing the treatment effect across participants with different levels of baseline proteinuria.
TVTX Ratings Summary
TVTX Quant Ranking